Stocks · News reference

OnKure Therapeutics Announces Registration Of Up To $100M At-The-Market Offering Of Class A Common Stock Through Leerink Partners

Aug 4, 2026, 9:22 PMBenzinga Newsdesk

https://www.sec.gov/Archives/edgar/data/1637715/000119312526332839/okur_424b5-20260804.htm

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 14, 2026, 5:15 PMBenzinga Newsdesk
Oppenheimer Reiterates Outperform on OnKure Therapeutics, Lowers Price Target to $14
Oppenheimer analyst Leland Gershell reiterates OnKure Therapeutics (NASDAQ:OKUR) with a Outperform and lowers the price target from $30 to $14.
Read original at benzinga
OKUR
SEC EDGARAug 12, 2026, 10:22 PMSEC EDGAR
8-K filing — OnKure Therapeutics, Inc. (OKUR)
Filed: 2026-08-13 AccNo: 0001193125-26-347315 Size: 158 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Read original at edgar
OKUR
BenzingaAug 4, 2026, 9:40 PMBenzinga Newsdesk
CORRECTION: OnKure Therapeutics Q2 EPS $(0.31) Beats $(0.54) Estimate
OnKure Therapeutics (NASDAQ:OKUR) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.54) by 41.51 percent. This is a 72.81 percent increase over losses of $(1.14) per share
Read original at benzinga
OKUR